Brought to you by 
Genentech, Lexicon expand 2002 drug discovery deal
13 Jul 2006
Executive Summary
Genentech and Lexicon Genetics have expanded their 2002 drug and antibody target discovery deal for another three years. Lexicon will use its gene knockout technology to further research and validate targets from Genentech's Secreted Protein Discovery program that were discovered under their previous research alliance.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Includes Contract
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Genentech, Lexicon expand 2002 drug discovery deal
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice